English  |  正體中文  |  简体中文  |  Items with full text/Total items : 65421/65421 (100%)
Visitors : 22354361      Online Users : 190
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.lib.ncu.edu.tw/handle/987654321/70366


    Title: 前列腺癌增殖與轉移分子機轉及天然物治療之研究;MOLECULAR MECHANISMS OF THE PROLIFERATION AND METASTASIS OF PROSTATE CANCER AND NATURAL COMPOUNDS THERAPIES
    Authors: 霍捷,;Chieh,Huo
    Contributors: 生命科學系
    Keywords: 前列腺癌;轉移分子機轉;天然物治療;PROSTATE CANCER;METASTASIS;NATURAL COMPOUNDS
    Date: 2016-05-27
    Issue Date: 2016-06-04 13:04:26 (UTC+8)
    Publisher: 國立中央大學
    Abstract: 中文摘要
    前列腺癌是男性發生率第二高的癌症,並為世界第五最常見的癌症。前列腺癌病患接受雄激素治療以及去勢後腫瘤萎縮,但平均在1-3年內前列腺癌將會復發,希望能找尋潛在治療目標和晚期前列腺癌有效治療方法。
    章3-1:我們發現了兩個天然化合物,蜂膠萃取物(CAPE)以及膽甾-3,5,6三醇,這兩種天然化合物顯示出對於前列腺癌細胞抗腫瘤活性具有療效。前列腺癌細胞LNCaP、104-R1、DU-145、22RV1、C4-2經由CAPE的誘導G1或G2 / M期的細胞週期停滯抑制細胞存活和去勢抗性前列腺癌(CRPC)細胞增殖的影響。CAPE經由調控Skp2的,P53,P21CIP1,和p27kip1而誘導細胞週期阻滯和生長抑制CRPC細胞。
    章3-2:膽-3,5,6三醇經腹腔注射動物實驗後能有效抑制DU-145異種移植腫瘤體積減少了36%,膽甾-3,5,6三醇引發的前列腺癌細胞凋亡,G1細胞週期停滯。根據我們的研究結果,膽甾3,5,6三醇和CAPE將是晚期前列腺癌的有潛力的天然藥物。
    章3-3:雄激素受體(AR)在前列腺癌的發生中有者不可或缺的作用。然而AR對前列腺癌轉移的作用尚不完全清楚。我們觀察到當AR過度表現在未具有AR的前列腺癌細胞之中,將抑制癌細胞運動及轉移。根據我們的研究結果,過度表現AR的PC-3細胞通過調控EMT標誌物蛋白和MMP活性可抑制細胞轉移和侵襲。
    章3-4:藉由病人臨床樣品基因表現,發現相較於正常前列腺組織AKT3的mRNA表現量比早期未轉移前列腺腫瘤更低。AKT3蛋白表達在階段I,II,III的前列腺腫瘤較高於正常組織。 AKT3過度表達促進的列腺癌細胞的增殖,LNCaP、PC-3、DU-145和CA-HPV-10細胞。根據我們的研究結果AKT3的表達提供前列腺癌細胞生長優勢,然而AKT3可用於前列腺癌治療的潛在治療靶標指標。
    我們發現PI3 / AKT激酶信號傳導途徑和雄激素受體(AR)在前列腺癌細胞的增殖和轉移的調控中發揮重要作用。 AKT3促進增殖抑制毛刺前列腺癌細胞的遷移和侵襲。 AR似乎是前列腺癌轉移腫瘤抑制。我們還確定了天然化合物CAPE和膽-3,5,6三醇成為去勢抵抗前列腺癌(CRPC)細胞的潛在治療藥物。根據我們的研究結果揭示了潛在治療目標和治療晚期前列腺癌潛力藥物。
    ;Prostate cancer is the second most frequently diagnosed cancer of men and the fifth most common cancer overall in the world. This disease is one of the most common non-cutaneous carcinoma of men in Western countries. Prostate cancer patients receiving androgen ablation therapy ultimately develop recurrent castration-resistant prostate cancer within 1-3 years.
    Chapter 3-1: We discovered two natural compounds, caffeic acid phenethyl ester (CAPE) and cholestane-3, 5, 6-triol, exhibiting anti-cancer activity against prostate cancer cells. Treatment with CAPE suppressed cell survival and proliferation of castration-resistant prostate cancer (CRPC) cell via induction of G1 or G2/M cell cycle arrest in LNCaP 104-R1, DU-145, 22Rv1, and C4-2 CRPC cells. Our finding suggested that CAPE treatment induced cell cycle arrest and growth inhibition in CRPC cells via regulation of Skp2, p53, p21Cip1, and p27Kip1.
    Chapter 3-2: Cholestane-3, 5, 6-triol is one of the most abundant and active oxysterol. Intraperitoneal injection of 1 mg of cholestane-3, 5, 6-triol daily for 14 days caused a 36% reduction in average volume of DU-145 xenograft. Cholestane-3, 5, 6-triol selectively suppressed proliferation of prostate cancer cells compared to normal prostate epithelial cells with IC50 ranging from 12-31 M. Cholestane-3, 5, 6-triol caused apoptosis, G1 cell cycle arrest, loss of -actin, and redistribution of -tubulin in prostate cancer cells. Our observations suggested that cholestane-3, 5, 6-triol and CAPE are potential chemotherapy agents for advanced prostate cancer.
    Chapter 3-3: Androgen receptor (AR) plays essential role during development and progression of prostate cancer. However, the role of AR on prostate cancer metastasis is not fully understood. We observed that re-expression of AR, which locates in cytoplasmic in the absence of androgen, suppressed cell motility, migration, and invasion of PC-3 cells as determined by wound healing assay and transwell assay. Migration and invasion of PC-3 and PC-3AR cells was promoted by EGF or IGF-1 but was suppressed by Casodex. Re-expression of AR reduced activity of MMP-2 and MMP-9 in PC-3 cells. Our observations suggested that re-expressing AR suppresses migration and invasion of PC-3 cells via regulation of EMT marker proteins and MMP activity.
    Chapter 3-4: Online database of clinical samples, including PubMed GEO profile or Oncomine, indicated that Akt3 mRNA expression level was higher in primary prostate tumors as compared to the normal prostate tissues. Immunohistochemical staining of 65 clinical samples revealed that Akt3 protein expression was higher in prostate tumors of stage I, II, III as compared to nearby normal tissues. Plasmid overexpression of Akt3 promoted cell proliferation of LNCaP, PC-3, DU-145, and CA-HPV-10 human prostate cancer cells, while knockdown of Akt3 by siRNA reduced cell proliferation in these cancer cells. Our observations implied that expression of Akt3 provides growth advantage for prostate cancer cells and Akt3 may be a potential therapeutic target for prostate cancer treatment.
    We discovered that PI3/AKT kinase signaling pathway and androgen receptors (AR) play essential roles in regulation of proliferation and metastasis of prostate cancer cells. AKT3 promotes proliferation bur suppresses migration and invasion of prostate cancer cells. AR seems to be a tumor suppressor on prostate cancer metastasis. We also identified natural compounds CAPE and cholestane-3beta, 5alpha, 6beta-triol to be potential therapeutic agents for castration-resistant prostate cancer (CRPC) cells. In conclusion, our studies revealed potential therapeutic targets and treatments for advanced PCa
    Appears in Collections:[生命科學研究所 ] 博碩士論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML373View/Open


    All items in NCUIR are protected by copyright, with all rights reserved.

    社群 sharing

    ::: Copyright National Central University. | 國立中央大學圖書館版權所有 | 收藏本站 | 設為首頁 | 最佳瀏覽畫面: 1024*768 | 建站日期:8-24-2009 :::
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback  - 隱私權政策聲明